TBPH Share Price Performance
US$16.72
7.59 (83.13%)
3.4% overvalued intrinsic discount
US$16.17
Fair Value
Price US$16.72
AnalystConsensusTarget US$16.17
AnalystHighTarget US$26.00
AnalystLowTarget US$15.00
Fair ValueUS$16.17
Share Pricen/a
Theravance Biopharma, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
TBPH Community Narratives
AN
Fair Value US$16.17 3.4% overvalued intrinsic discount
Chronic And Respiratory Care Will Fuel Future Market Expansion
1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$26 35.7% undervalued intrinsic discount
YUPELRI And Ampreloxetine Will Capitalize On Secular Trends
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$15 11.5% overvalued intrinsic discount
Government Scrutiny Will Challenge Outlook While Offering Fragile Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Government Scrutiny Will Challenge Outlook While Offering Fragile Upside
Key Takeaways Heavy reliance on a limited product lineup raises vulnerability to pricing pressures, generic competition, and uncertain future revenue streams. Heightened regulatory, payer, and industry challenges may dampen profitability and hinder the successful commercial launch of new drug candidates.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
11.5% overvalued intrinsic discount
Fair Value
Revenue
-8.86% p.a.
Profit Margin
6.22%
Future PE
203.29x
Price in 2029
US$18.29
Chronic And Respiratory Care Will Fuel Future Market Expansion
Key Takeaways Sustained demand for key therapies and new product approvals support revenue growth, expanded margins, and enhanced operating leverage in both established and emerging markets. Streamlined cost structure, controlled spending, and a robust cash position reduce financial risk while enabling reinvestment in pipeline assets and supporting future earnings growth.Read more
67
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$16.17
3.4% overvalued intrinsic discount
Fair Value
Revenue
-5.03% p.a.
Profit Margin
46.32%
Future PE
26x
Price in 2029
US$19.71
YUPELRI And Ampreloxetine Will Capitalize On Secular Trends
Key Takeaways YUPELRI and ampreloxetine are positioned for market leadership and profit growth, with potential to outperform current expectations in both COPD and rare disease segments. Strong financial discipline and underappreciated global opportunities enhance Theravance's ability to accelerate shareholder returns and capitalize on emerging high-margin revenue streams.Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$26
35.7% undervalued intrinsic discount
Fair Value
Revenue
22.99% p.a.
Profit Margin
39.91%
Future PE
29.81x
Price in 2028
US$31.59
Trending Discussion
Recently Updated Narratives
AN
TBPH: Future Returns Will Depend On Cost Cuts After Ampreloxetine Failure
Fair Value: US$15 11.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TBPH: Cost Reset And Cash Reserves Will Shape Post Ampreloxetine Future
Fair Value: US$16.17 3.4% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
YUPELRI And Ampreloxetine Will Capitalize On Secular Trends
Fair Value: US$26 35.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Theravance Biopharma, Inc. Key Details
About TBPH
- Founded
- 2013
- Employees
- 90
- CEO
- WebsiteView website
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
